Navigation Links
Pathfinder Initiates Minimally Invasive Surgical Navigation Study
Date:11/15/2010

NASHVILLE, Tenn., Nov. 15, 2010 /PRNewswire/ -- Pathfinder Therapeutics, Inc. has initiated a clinical study to assess the value of Explorer™, its image-guided surgical platform, in minimally invasive liver resections and ablations.  Clinical sites participating in the study include: Memorial Sloan-Kettering Cancer Center, University of Pittsburgh Medical Center, Providence Portland Medical Center, and UNC-Chapel Hill.

Minimally invasive procedures are performed through a few small incisions rather than one large incision.  As a result, these techniques can significantly reduce postoperative pain and patient recovery time compared with traditional surgery.

"We are excited to partner with these highly-regarded institutions to build upon the success of previous clinical studies showing that Explorer™ can provide accurate instrument tracking and guidance during open liver procedures. Despite its known benefits, minimally invasive liver surgery has not attained widespread use, in part due to the advanced skills and technological experience required to perform such procedures safely.  Explorer™ combines state-of-the-art surgical navigation and 3D visualization of preoperative imaging, thereby facilitating the transition from standard techniques to novel laparoscopic techniques for surgeons with less experience and formal training while also providing assistance to highly experienced surgeons," said Skip Goode, CEO of Pathfinder.

As part of the study, preoperative CT or MR imaging is registered to the intraoperative position of the liver, providing surgeons with enhanced visualization of the liver anatomy as well as real-time positioning of surgical instruments, including resection and ablation devices.  Rather than guess where underlying vessels and tumors are, surgeons can be confident they are precisely targeting the anatomical structures they have planned on, thus minimizing costly mistakes which can increase the risk of postoperative complications.  This ability to "see through the liver" in 3D is especially helpful during minimally invasive procedures, where the surgeon is unable to physically manipulate the liver as is possible during traditional surgery.

About Pathfinder Therapeutics, Inc.

Pathfinder Therapeutics, Inc. is a medical device company dedicated to increasing the number and effectiveness of surgeries on abdominal and other soft tissue organs.  Pathfinder is the first company to receive FDA clearance for a medical device to navigate liver surgery using preoperative medical images. The Explorer™ navigation system uses state-of-the-art optical tracking and surface registration techniques to show surgeons where they are in the context of their target organ and underlying structures.  For more information, go to www.pathsurg.com.


'/>"/>
SOURCE Pathfinder Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. American Regent Initiates Voluntary Recall of Magnesium Sulfate Injection, USP 50% (25 grams/50 mL), 50mL Single Dose Vial Lot # 0491
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
5. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
8. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
9. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
10. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
11. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... CHAPEL HILL, N.C. , Feb. 12, 2016  Clinical Affairs ... their clinical presence in emerging areas of the world. While some ... regions, others lag in their clinical activity in countries such as ... China and India ... approvals to market products in those countries. --> ...
(Date:2/12/2016)... , Feb. 12, 2016   National Community Pharmacists ... RPh, MBA issued the following statement today in response ... by the Centers for Medicare & Medicaid Services ... NCPA, beneficiary advocates and others: patient advocacy ... are still reviewing the full CMS analysis. Our initial ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... , ... February 12, 2016 ... ... today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced ... will recruit top students from U.S. universities who will draw from Siemens’ ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, ...
Breaking Medicine News(10 mins):